Daryl J Kor1, Remzi Iscimen, Murat Yilmaz, Michael J Brown, Daniel R Brown, Ognjen Gajic. 1. Division of Critical Care Medicine, Department of Anesthesiology, Multidisciplinary Epidemiology and Translational Research in Intensive Care, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. kor.daryl@mayo.edu
Abstract
PURPOSE: Preclinical studies suggest that HMG-CoA reductase inhibitors (statins) may attenuate organ dysfunction. We evaluated whether statins are associated with attenuation of lung injury and prevention of associated organ failure in patients with ALI/ARDS. METHODS: From a database of patients with ALI/ARDS, we determined the presence and timing of statin administration. Main outcome measures were the development and progression of pulmonary and nonpulmonary organ failures as assessed by changes in PaO(2)/FiO(2) ratio and Sequential Organ Failure Assessment score (SOFA) between days 1 and 7 after the onset of ALI/ARDS. Secondary outcomes included ventilator free days, ICU and hospital mortality, and lengths of ICU and hospital stay. RESULTS: From 178 patients with ALI/ARDS, 45 (25%) received statin therapy. From day 1 to day 7, the statin group showed less improvement in their PaO(2)/FiO(2) ratio (27 vs. 55, P = 0.042). Ventilator free days (median 21 vs. 16 days, P = 0.158), development or progression of organ failures (median DeltaSOFA 1 vs. 2, P = 0.275), ICU mortality (20% vs. 23%, P = 0.643), and hospital mortality (27 vs. 37%, P = 0.207) were not significantly different in the statin and non-statin groups. After adjustment for baseline characteristics and propensity for statin administration, there were no differences in ICU or hospital lengths of stay. CONCLUSION: In this retrospective cohort study, statin use was not associated with improved outcome in patients with ALI/ARDS. We were unable to find evidence for protection against pulmonary or nonpulmonary organ dysfunction.
PURPOSE: Preclinical studies suggest that HMG-CoA reductase inhibitors (statins) may attenuate organ dysfunction. We evaluated whether statins are associated with attenuation of lung injury and prevention of associated organ failure in patients with ALI/ARDS. METHODS: From a database of patients with ALI/ARDS, we determined the presence and timing of statin administration. Main outcome measures were the development and progression of pulmonary and nonpulmonary organ failures as assessed by changes in PaO(2)/FiO(2) ratio and Sequential Organ Failure Assessment score (SOFA) between days 1 and 7 after the onset of ALI/ARDS. Secondary outcomes included ventilator free days, ICU and hospital mortality, and lengths of ICU and hospital stay. RESULTS: From 178 patients with ALI/ARDS, 45 (25%) received statin therapy. From day 1 to day 7, the statin group showed less improvement in their PaO(2)/FiO(2) ratio (27 vs. 55, P = 0.042). Ventilator free days (median 21 vs. 16 days, P = 0.158), development or progression of organ failures (median DeltaSOFA 1 vs. 2, P = 0.275), ICU mortality (20% vs. 23%, P = 0.643), and hospital mortality (27 vs. 37%, P = 0.207) were not significantly different in the statin and non-statin groups. After adjustment for baseline characteristics and propensity for statin administration, there were no differences in ICU or hospital lengths of stay. CONCLUSION: In this retrospective cohort study, statin use was not associated with improved outcome in patients with ALI/ARDS. We were unable to find evidence for protection against pulmonary or nonpulmonary organ dysfunction.
Authors: Olaf Schouten; Niels F M Kok; Eric Boersma; Jeroen J Bax; Harm H H Feringa; Radosav Vidakovic; Randolph G Statius van Eps; Marc R H M van Sambeek; Don Poldermans Journal: Am J Cardiol Date: 2006-03-20 Impact factor: 2.778
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Babu V Naidu; Steven M Woolley; Alexander S Farivar; Robert Thomas; Charles Fraga; Michael S Mulligan Journal: J Thorac Cardiovasc Surg Date: 2003-08 Impact factor: 5.209
Authors: Ednan K Bajwa; Cindy K Malhotra; B Taylor Thompson; David C Christiani; Michelle N Gong Journal: Crit Care Med Date: 2012-05 Impact factor: 7.598
Authors: David Amar; Bernard Park; Hao Zhang; Weiji Shi; Martin Fleisher; Howard T Thaler; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2014-12-18 Impact factor: 5.209
Authors: Holger C Müller; Katharina Hellwig; Simone Rosseau; Thomas Tschernig; Andreas Schmiedl; Birgitt Gutbier; Bernd Schmeck; Stefan Hippenstiel; Harm Peters; Lars Morawietz; Norbert Suttorp; Martin Witzenrath Journal: Crit Care Date: 2010-07-30 Impact factor: 9.097
Authors: Steffen Christensen; Reimar W Thomsen; Martin B Johansen; Lars Pedersen; Reinhold Jensen; Kim M Larsen; Anders Larsson; Else Tønnesen; Henrik Toft Sørensen Journal: Crit Care Date: 2010-03-09 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-02-23 Impact factor: 17.440